ALK and non-small cell lung carcinoma: However, mortality from NSCLC has been declining, in part due to the advent of targeted therapies for driver mutations such as EGFR and MET (exon 14) and fusions such as ALK, ROS1, NTRK1/2/3, and RET [2].